Pronova BioPharma has evolved from a long history of development and strategic growth, the key aspects of which are as follows:
-
1935: A marine oil processing factory was established by Jahres Fabrikker and Johan C Martens & Company in Norway
-
1986 to 1988: Norsk Hydro acquired the two companies to develop its omega-3 fish oil containing EPA and DHA
-
1988: Patent protection in the UK for product composition and therapeutic use of the active pharmaceutical ingredient was filed
-
1992: The patent was granted and gave coverage in 26 countries. Johan C Martens & Company and Jahres Fabrikker merged to form Pronova
Biocare
-
1994: Registration of the HTG indication in Europe was granted with the commercial launch in Italy
-
1999: Registration of the active pharmaceutical ingredient for the Post-MI indication in Europe was granted
-
2004 to 2005: Ferd Private Equity Fund I acquired Pronova Biocare. Consumer and industrial brands were sold
-
2004: FDA approval of Omacor® and Lovaza™ for the HTG indication and treatment as an adjunct to diet for patients with “very high”
levels of triglycerides in the USA
-
2007: Change of name to Pronova BioPharma. Listing of the company’s shares on the Oslo Stock Exchange
-
2009: A new manufacturing plant in Kalundborg, Denmark became operational and was approved by European authorities, doubling the
group’s production capacity. The product achieved blockbuster status with end-user sales above USD 1 billion
